Moderna Inc. said it had started a study of a booster shot that combines a formulation designed to fend off the omicron variant with the company’s current Covid-19 vaccine.
The company said in a statement Thursday that the first participant in the study had been given the experimental shot. Moderna plans to enroll about 375 people in the trial, which it said will be conducted at about 20 sites in the U.S.
